13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • CEND1-001

    Acronym: 

    CEND1-001

    ACTRN/NCT /ethics: 

    NCT03517176

    Scientific title: 

    CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

    Summary of trial and patient characteristics

    Cancer Type Pancreas
    Trial Type Treatment
    Phase Phase I Tumour Stream Pancreatic
    Age Range 18 years and older Cancer Stage Metastatic or Widespread
    Sex Both Anticipated Start Date 2018-07-31
    Molecular Target Anticipated End Date
    Cancer Type Pancreas
    Trial Type Treatment
    Phase Phase I
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Pancreatic
    Cancer Stage Metastatic or Widespread
    Anticipated Start Date 2018-07-31
    Anticipated End Date

    Trial Summary

    A phase I trial of CEND-1 in combination with nabpaclitaxel and gemcitabine in metastatic exocrine pancreatic cancer.

    Lay Summary

    CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

    Sponsor / Cooperative group

    DrugCendR Inc.

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Queen Elizabeth Hospital Sue Yeend Sue.Yeend@sa.gov.au 08 8222 6148 Professor Tim Price Recruiting